CANADA LIFE ASSURANCE Co Has $20.96 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

CANADA LIFE ASSURANCE Co cut its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 27.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 269,760 shares of the medical device company's stock after selling 100,376 shares during the period. CANADA LIFE ASSURANCE Co owned about 0.07% of DexCom worth $20,961,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the business. Versant Capital Management Inc bought a new position in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA grew its holdings in shares of DexCom by 266.3% in the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock worth $26,000 after acquiring an additional 245 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC lifted its stake in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after buying an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter worth about $38,000. Institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Citigroup upped their price target on shares of DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Robert W. Baird upgraded shares of DexCom from a "neutral" rating to an "outperform" rating and increased their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Baird R W upgraded DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Wells Fargo & Company reaffirmed an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Finally, Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research note on Friday, February 14th. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Trading Up 5.9 %

Shares of NASDAQ:DXCM traded up $3.92 during midday trading on Thursday, hitting $70.78. 3,922,772 shares of the stock were exchanged, compared to its average volume of 4,238,457. The business's 50-day moving average price is $73.83 and its 200 day moving average price is $76.60. The stock has a market capitalization of $27.75 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a 12 month low of $57.52 and a 12 month high of $139.24. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other DexCom news, CEO Kevin R. Sayer sold 33,359 shares of the firm's stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the completion of the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. This represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock valued at $8,044,178 in the last ninety days. 0.32% of the stock is owned by company insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.